Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Can-Fite BioPharma Ltd.
< Previous
1
2
3
Next >
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
November 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
October 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
October 26, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
October 09, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
September 27, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
September 07, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
August 31, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
August 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
August 18, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
July 17, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
July 07, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
June 29, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
June 13, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
June 02, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
June 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
May 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
May 15, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
May 09, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
May 02, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
April 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
April 10, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
March 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
March 16, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
March 13, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
February 14, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
January 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
January 11, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
January 10, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Announces ADS Ratio Change
December 30, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
December 28, 2022
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Tickers
CANF
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.